October 13, 2016
STENTYS sees revenue up 26%over the first 9 months
STENTYS a medical technology company today announced its revenue for the third quarter and first 9 months to September 30, 2016.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Business
September 28, 2016
Pfizer decides against split-up; more deals seen likely
Pfizer, which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
September 12, 2016
Horizon buys Raptor for $800M
Horizon Pharma and Raptor Pharmaceutical Corp.have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued…
September 12, 2016
New Board member to Verona Pharma
Verona Pharma #VRP appoints Vikas Sinha to the Board as a Non-Executive Director
July 29, 2016
Sanofi reports net income €1,158m, down 11.1%
“Second quarter financial performance was in-line with expectations.” – Olivier Brandicourt, Sanofi CEO
July 25, 2016
Faron and Abzena in cancer medicine Clevegen manufacture deal
Faron and Abzena in cancer medicine Clevegen manufacture deal
July 8, 2016
PureTech Health introduces new members to its Scientific Advisory Board
PureTech Health has introduced new members to its Scientific Advisory Board
April 8, 2016
Allergan and Heptares team up for novel treatments in Alzheimer’s
Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.
April 5, 2016
New U.S. inversion rules threaten Pfizer-Allergan deal
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
March 22, 2016
Drugmaker Valeant CEO leaving as investor Ackman joins the board
Drugmaker Valeant Pharmaceuticals International Inc said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.